RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret Past Earnings Performance
Past criteria checks 0/6
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret's earnings have been declining at an average annual rate of -5.7%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 3.5% per year. RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret's return on equity is 1.1%, and it has net margins of 82.6%.
Key information
-5.7%
Earnings growth rate
-8.9%
EPS growth rate
Biotechs Industry Growth | 14.8% |
Revenue growth rate | 3.5% |
Return on equity | 1.1% |
Net Margin | 82.6% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 107 | 89 | 19 | 19 |
30 Jun 24 | 106 | -414 | 30 | 16 |
31 Mar 24 | 101 | 129 | 33 | 14 |
31 Dec 23 | 96 | 0 | 31 | 15 |
30 Sep 23 | 184 | 174 | 59 | 17 |
30 Jun 23 | 181 | 244 | 57 | 16 |
31 Mar 23 | 176 | -46 | 55 | 16 |
31 Dec 22 | 191 | -20 | 55 | 14 |
30 Sep 22 | 203 | 223 | 33 | 17 |
30 Jun 22 | 299 | 146 | 39 | 18 |
31 Mar 22 | 368 | 124 | 41 | 19 |
31 Dec 21 | 384 | 114 | 41 | 17 |
30 Sep 21 | 373 | 113 | 40 | 9 |
30 Jun 21 | 307 | 87 | 35 | 8 |
31 Mar 21 | 267 | 76 | 37 | 6 |
31 Dec 20 | 230 | 61 | 31 | 5 |
30 Sep 20 | 127 | 49 | 20 | 4 |
30 Jun 20 | 85 | 34 | 13 | 4 |
31 Mar 20 | 34 | 12 | 5 | 4 |
31 Dec 19 | 17 | 4 | 5 | 4 |
30 Sep 19 | 19 | 7 | 6 | 6 |
30 Jun 19 | 19 | 8 | 7 | 5 |
31 Mar 19 | 21 | 4 | 7 | 4 |
31 Dec 18 | 20 | 2 | 7 | 4 |
30 Sep 18 | 24 | 2 | 7 | 2 |
30 Jun 18 | 29 | 2 | 7 | 3 |
31 Mar 18 | 35 | 3 | 7 | 3 |
31 Dec 17 | 38 | 4 | 7 | 3 |
30 Sep 17 | 38 | 5 | 8 | 2 |
30 Jun 17 | 36 | 3 | 8 | 2 |
31 Mar 17 | 33 | 3 | 8 | 2 |
31 Dec 16 | 32 | 4 | 8 | 2 |
30 Sep 16 | 31 | 4 | 8 | 2 |
30 Jun 16 | 33 | 6 | 8 | 2 |
31 Mar 16 | 34 | 7 | 6 | 2 |
31 Dec 15 | 34 | 7 | 7 | 2 |
30 Sep 15 | 31 | 7 | 7 | 2 |
30 Jun 15 | 31 | 6 | 8 | 1 |
31 Mar 15 | 28 | 5 | 7 | 1 |
31 Dec 14 | 26 | 5 | 6 | 1 |
30 Sep 14 | 24 | 4 | 5 | 1 |
30 Jun 14 | 21 | 5 | 3 | 1 |
31 Mar 14 | 20 | 5 | 3 | 1 |
31 Dec 13 | 19 | 4 | 3 | 1 |
Quality Earnings: RTALB has a high level of non-cash earnings.
Growing Profit Margin: RTALB's current net profit margins (82.6%) are lower than last year (94.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RTALB's earnings have declined by 5.7% per year over the past 5 years.
Accelerating Growth: RTALB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RTALB had negative earnings growth (-48.9%) over the past year, making it difficult to compare to the Biotechs industry average (5.5%).
Return on Equity
High ROE: RTALB's Return on Equity (1.1%) is considered low.